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ulceration or irregularity. The CAG revealed that 49 cases 
had ACS lesions to be indicated for emergency PCI. The 
areas under the ROC curves and ROC-optimized cut-off 
of hs-TnT, c-TnT, CK-MB, and H-FABP were 0.75, 0.67, 
0.68, and 0.75, respectively, and 18, 11, 2.0, and 4.6 ng/ml, 
respectively. In patients with total occlusion and 90–99 % 
of diameter stenosis (TIMI 2 or 3), hs-TnT could pre-
dict emergency PCI with significantly higher sensitivity 
compared with H-FABP (hs-TnT >14 ng/ml; 71 %, and 
H-FABP >6.2 ng/dl; 51 %, p = 0.021) and other biomark-
ers. Meanwhile, H-FABP displayed significant correlations 
with number of diseased vessels and presence of throm-
botic lesion. The present study first revealed different char-
acteristics of correlation between the angiographic culprit 
lesions and each cardiac biomarker. For prediction of ACS 
lesions requiring emergency PCI, hs-TnT had the highest 
sensitivity with satisfied analytical precision.
Keywords High-sensitivity troponin T · Heart-type fatty 
acid-binding protein · Acute coronary syndrome · Coronary 
angiography · Culprit lesion
Abbreviations
ACS  Acute coronary syndrome
AMI  Acute myocardial infarction
CAG  Coronary angiography
CK-MB  Creatine kinase MB isozyme
c-TnT  Conventional troponin T
hs-TnT  High-sensitivity troponin T
HsTnT-iNET  High-sensitivity troponin T for earlier 
diagnosis of acute myocardial infarction in 
patients with initially negative troponin T 
test
H-FABP  Heart-type fatty acid-binding protein
LCX  Left circumflex artery
Abstract This multicenter prospective study was con-
ducted to assess high-sensitivity troponin T (hs-TnT) and 
other biomarkers to decide and predict culprit lesions 
indicated for emergency percutaneous coronary inter-
vention (PCI) in patients with suspicious acute coronary 
syndrome (ACS). We have reported Hs-TnT is the most 
sensitive biomarker for earlier diagnosis and decision mak-
ing in patients with suspected ACS. In this study, we had 
conducted subanalysis investigating the usefulness for 
prediction of ACS culprit lesion. The patients with suspi-
cious ACS and initially negative whole-blood rapid tro-
ponin T test, who underwent coronary angiogram (CAG), 
were enrolled (n = 74). Hs-TnT, quantitative assay for 
conventional troponin T (c-TnT), creatine kinase MB 
isozyme (CK-MB), and heart-type fatty acid-binding pro-
tein (H-FABP) were simultaneously measured. ACS culprit 
lesion was described as total occlusion, subtotal occlusion, 
and/or angiographical unstable lesion such as thrombosis, 
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PCI  Percutaneous coronary intervention
%DS  Percentage diameter stenosis
RCA  Right coronary artery
ROC  Receiver operator characteristics
Introduction
An early diagnosis is of absolute necessity for appropriate 
therapeutic decision and risk stratification in patients with 
acute coronary syndrome (ACS). Cardiac troponin meas-
urement has become essential in the diagnosis of acute 
myocardial infarction (AMI) according to the ESC/ACC 
Task Force redefinition of myocardial infarction [1]. More-
over, as the Joint ESC/ACC/AHA/WHF Task Force pre-
sented in the universal definition of myocardial infarction 
in 2007 [2], the diagnosis of AMI is accurately determined 
based on a rise and/or fall in cardiac biomarkers with at 
least one value above the 99th percentile of the upper refer-
ence limit.
We have reported the excellent diagnostic performance 
of high-sensitivity troponin T (hs-TnT) in comparison 
with other cardiac biomarkers in the HsTnT-iNET (High-
Sensitivity cardiac Troponin T for earlier diagnosis of acute 
myocardial infarction in patients with an Initially NEgative 
Troponin T test) study [3]. In brief, the HsTnT-iNET study 
demonstrated that hs-TnT displayed the highest sensitivity 
among the validated cardiac markers, that is the sensitivity 
and NPV of hs-TnT were both 100 % for AMI diagnosis 
after 120 min from the onset.
The coronary angiography (CAG) as well as cardiac 
biomarker has been a gold standard for the contemporary 
practice to diagnose and to make the therapeutic decision 
for ACS. However, there was little evidence in the investi-
gation of cardiac biomarkers in comparison with the find-
ings of CAG. Therefore, we conducted an additional analy-
sis to investigate the diagnostic performance of the cardiac 
biomarkers to predict presence of culprit lesions for emer-
gency percutaneous coronary intervention (PCI) in ACS.
Materials and methods
Study design and population
The present HsTnT-iNET substudy was a prospective mul-
ticenter study including 5 participating tertiary centers 
equipped with coronary care units in Japan. From Novem-
ber 2009 through January 2011, patients who presented at 
the emergency room with symptoms suggestive of AMI and 
initially negative TnT were enrolled in the present study. 
This study was conducted according to the principles of the 
Declaration of Helsinki and the protocol was approved by 
the ethics committee at each participating institution. Writ-
ten informed consent was obtained from all patients in the 
emergency room.
Final diagnosis was adjudicated based on the initial 
diagnosis and diagnosis at discharge from the hospital, 
and electrocardiogram (ECG) changes during hospitaliza-
tion. In the present CAG study, we conducted an additional 
subanalysis, and the raw data of ECG and CAG were col-
lected to analyze precise correlations between the cardiac 
biomarkers elevation and the culprit lesions characteristics.
Out of 85 patients with negative c-TnT test (<100 ng/L) 
assigned to the HsTnT-iNET study, total of 74 patients 
who underwent CAG were included in this CAG analy-
sis (Fig. 1). The baseline characteristics of the patients 
and the details of diagnosis are presented in Table 1. The 
median age was 70 years (IQR 66–75). The median time 
from the onset of symptoms to drawing of first blood sam-
ple was 135 min (IQR 99–165). Ischemic ST-T findings 
of ECG were confirmed in 62 patients (84 %) at presen-
tation, with ST-segment elevation being most frequently 
detected [n = 44 (59 %)]. The details of treatments within 
48 h from presentation are shown in Table 1. Thirty-seven 
patients (50 %) were classified as having ST-segment ele-
vation MI (STEMI) and 7 patients (9 %) as having non-ST-
segment elevation MI (NSTEMI). There were 40 patients 
(54 %) in Killip class I, 3 (4 %) in class II, and 1 (1 %) in 
class III. Type 4a MI was not detected in the present study 
population.
Blood sampling and validated cardiac biomarkers
Blood samples were drawn during the acute phase, at 
presentation (T0), 3, and 6 h after the T0 sampling. If the 
whole-blood rapid TnT test was positive (conventional 
TnT≧100 ng/L) at presentation (T0), the patients were 
excluded from the present study. Immediately after cen-
trifugation, the sample serum was stored at −80° until 
each measurement was performed. The levels of conven-
tional troponin T (c-TnT), and creatine kinase MB isozyme 
(CK-MB) were measured by an electrochemiluminescence 
immunoassay with the Roche Modular Analytics E170®. 
Hs-TnT was measured by an electrochemiluminescence 
immunoassay with the ECLusys®/Elecsys® hs-TnT 2010 
Roche diagnostics assay. The analytical characteristics of 
the troponin assays have been reported at http://www.ifcc.
org. In the c-TnT assay, the 99th percentile of the upper 
reference limit, coefficient of variance at the 99th percen-
tile, and the value with a 10 % coefficient of variance were 
calculated to be 10 ng/L, 18 %, and 30 ng/L, respectively. 
Therefore, the cut-off value for a diagnosis of AMI was 
defined as 30 ng/L because the precision was unsatisfactory 
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at the 99th percentile. In the CK-MB assay, the 97.5th 
percentile of the upper reference limit was reported to be 
3.1 ng/ml, and the coefficient of variance at 8.2 ng/ml was 
calculated to be 3.1 %. The cut-off value of CK-MB at 
5.0 ng/ml had been used for the diagnosis of AMI, which 
fulfilled required analytical precision. The serum concen-
tration of heart-type fatty acid-binding protein (H-FABP) 
was measured by an enzyme-linked immunosorbent assay.
The cut-off values of hs-TnT, c-TnT, CK-MB, and 
H-FABP were defined as 14 ng/L (the value at 99th per-
centile upper reference limit), 30 ng/L (the value for 10 % 
coefficient of variance), 5.0, and 6.2 ng/L. The values of 
CK-MB and H-FABP had been currently used as the cut-
off point to diagnose MI in the clinical practice.
Coronary angiography
All patients enrolled in this subanalysis underwent CAG 
within 48 h from the onset of symptom. A significant ste-
nosis was defined as a percentage of diameter stenosis 
(%DS) > 75 %, and a severe stenotic lesion with 99–100 % 
stenosis was classified by Thrombolysis in Myocardial 
Infarction (TIMI) flow grade. (TIMI flow grade 3; full per-
fusion with normal flow, grade 2; perfusion of the entire 
vessel with delayed flow compared with a normal artery, 
grade 1; some penetration of the contrast material beyond 
the point of obstruction but without perfusion of the dis-
tal coronary bed, grade 0; complete occlusion) [4] In this 
study, the antegrade flow with TIMI flow grade 0 or 1 was 
defined as total occlusion, and that with TIMI flow grade 
2 or 3 was defined as subtotal occlusion. The collateral 
filling developed for the severe stenosis with total or subto-
tal occlusion was described as the grades reported by Rent-
rop (Collateral filling grade 0; none, grade 1; filling of side 
branches of the artery via collateral channels without visu-
alization of the epicardial segment, grade 2; partial filling 
of the epicardial segment via collateral channels, grade 3; 
complete filling of the epicardial segment of the artery via 
collateral channels) [5].
Angiographic ACS lesion was defined as total occlu-
sion, subtotal occlusion, or moderate stenosis with throm-
bosis, ulceration or irregularity. When the culprit lesion 
was not located in the main coronary vessel (right coronary 
artery, left main trunk artery, left anterior descending artery 
or left circumflex artery), but in the branch perfusing the 
lateral myocardium (i.e., diagonal branch, obscure mar-
ginal branch, intermediate artery), the culprit vessel was 
described as lateral branch. The CAG findings were inter-
preted by 2 interventional cardiologists (MK, NH) without 
the background information regarding cardiac biomarkers 
in the core laboratory.
Adjudication of the final diagnosis
To determine the final diagnosis for each patient, all case 
records collected from all participant institutes were 
reviewed, regarding the clinical diagnosis, coronary risk 
factors, time course from the onset of symptoms to pres-
entation, findings of the ECG at presentation and 24 h 
later, coronary angiography (CAG), and other examina-
tions and all medical treatments. The diagnosis of AMI 
was determined according to the universal definition of 
Fig. 1  Study population of 
HsTnT-iNET study and suba-
nalysis
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MI as we recently reported [3]. Vasospastic angina (VSA) 
was diagnosed for the patients with resting chest pain in 
the situations of no significant organic stenosis explain-
ing AMI or presence of the CAG-proved coronary spasm 
(>75 %) with or without provocation test (acetylcholine 
or ergonovine) [6–8]. We basically adopted the final diag-
nosis declared from the participating institution, if there 
was no discrepancy between the diagnosis and the col-
lected clinical findings. In patients with non-ST-segment 
elevation MI (NSTEMI) who received percutaneous coro-
nary intervention (PCI) before the second blood sampling, 
the cut-off point of c-TnT was defined as three times the 
99th percentile URL (90 ng/L), because myocardial injury 
could not be discriminated between AMI and peri-proce-
dural necrosis [9].
Interventional procedures
Interventional procedures for reperfusion were selected 
at operator’s discretion, included thrombectomy, balloon 
dilatation, stent implantation, and distal protection. We 
reviewed use of thrombus aspiration, stent, drug-eluting 
stent for revascularization, and final TIMI flow grade after 
the procedure. Temporary pacing, intra-aortic balloon 
pumping, and extracorporeal life support were indicated if 
necessary.
Table 1  Baseline 
characteristics of study 
population
MI myocardial infarction, EMS emergency medical service, eGFR estimated glomerular filtration rate, RAA 
renin–angiotensin–aldosterone, IABP intra-aortic balloon pumping, ECLS extracorporeal life support, PCI 
percutaneous coronary intervention, CABG coronary artery bypass graft, AP angina pectoris, VSA vasos-
pastic angina
Age, year Pharmacological therapy within 48 h, n (%)
 Median 70  Antiplatelet 70 (96)
 Interquartile range 66–75  Anticoagulant 65 (89)
Male sex, n (%) 67 (91)  Thrombolytic agent 0 (0)
Risk factors, n (%)  Nitrates 27 (37)
 Hypertension 61 (82)  Beta blocker 20 (27)
 Hyperlipidemia 41 (55)  RAA blocker 33 (45)
 Diabetes 18 (24)  Ca Channel Blocker 15 (21)
 Current smoking 27 (36)  IV-Nicorandil 36 (49)
Past history, n (%)  IV-Inotropes 8 (11)
 Coronary artery disease 18 (24) Mechanical support, n (%)
 Previous MI 4 (5)  Pacemaker 12 (16)
 Previous PCI 8 (11)  IABP 5 (7)
 Previous CABG 1 (1)  ECLS 0 (0)
Status of arrival, n (%) Invasive treatment, n (%)
 Walk-in 15 (20)  Coronary angiography 74 (100)
 EMS 55 (74)  PCI 52 (70)
 Helicopter EMS 5 (7)  CABG 0 (0)
 Referral from other clinic 15 (20) Final diagnosis, n (%)
Time from onset of chest pain, min  AMI 44 (59)
 Median 165   STEMI 37 (50)
 Interquartile range 100–327   NSTEMI 7 (9)
Electrocardiographic findings at presentation, n (%)    Killip Class I 40 (54)
 ST-segment elevation 44 (59) Class II 3 (4)
 ST-segment depression 11 (15) Class III 1 (1)
 T-wave inversion 7 (9) Class IV 0 (0)
 Abnormal Q wave 10 (14)  Non-AMI 30 (41)
 No significant findings 12 (16)   Unstable AP 12 (16)
eGFR   Stable AP 2 (3)
 Median, ml/min 76   VSA 10 (14)
 Interquartile range, ml/min 60–88   Other cardiac 1 (1)
 eGFR < 60 ml/min, n (%) 18 (24)   Non-cardiac 3 (4)
 eGFR < 30 ml/min, n (%) 2 (3)   Unknown 2 (3)
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Statistical analysis
Continuous variables are presented as the means (±standard 
deviation) or medians [the interquartile range]. Categorical 
variables are presented as numbers and percentages. The 
diagnostic performances of each assay were represented as 
the sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV), and receiver operating 
Table 2  Final diagnosis and angiographical result of study population
AMI acute myocardial infarction, STEMI ST-segment elevation myocardial infarction, NSTEMI non-ST-segment elevation myocardial infarction, 
AP angina pectoris, VSA vasospastic angina, CAD coronary artery disease, RCA right coronary artery, LAD left anterior descending artery, LCX 
left circumflex artery, LMT left main trunk artery, CABG coronary artery graft bypass
† p value <0.05 in max CPK
All patients (N = 74)
Diameter stenosis of  
the culprit lesion
All 
n = 74 (100)
100 % (TIMI 0–1) 99 % (TIMI 2) 90–99 % (TIMI 3) Spasm 0–75 %
Rentrop 0–1 Rentrop 2–3 Rentrop 0–1
n = 19 (26) n = 6 (8) n = 12 (16) n = 12 (16) n = 7 (9) n = 18 (24)
Adjudicated diagnosis
 AMI 44 (59) 19 (100) 5 (83) 9 (75) 7 (58) 2 (29) 2 (11)
  STEMI 37 (50) 19 (100) 3 (50) 9 (75) 3 (25) 2 (29) 1 (6)
  NSTEMI 7 (9) 0 2 (33) 0 4 (33) 0 1 (6)
 Unstable AP 12 (16) 0 1 (17) 3 (25) 5 (42) 0 3 (17)
 Stable AP 2 (3) 0 0 0 0 0 2 (11)
 VSA 10 (14) 0 0 0 0 5 (71) 5 (28)
 Non CAD 6 (8) 0 0 0 0 0 6 (33)
The details of angiography
 Spasm provocation test 5 (7) 0 0 0 0 4 (57) 1 (6)
 Diseased vessel
  RCA 25 (34) 10 (53) 4 (50) 6 (50) 2 (17) 2 (29) 1 (6)
  LAD 29 (39) 7 (37) 1 (17) 3 (25) 5 (42) 7 (100) 6 (33)
  LCX 8 (11) 1 (5) 1 (17) 2 (17) 3 (25) 1 (14) 0
  LMT 0 (0) 0 0 0 0 0 0
  Lateral branch 6 (8) 1 (5) 0 1 (8) 2 (17) 0 2 (11)
 Number of diseased vessel
  No significant stenosis 10 (14) 0 0 0 0 0 10 (56)
  1-vessel disease 50 (68) 14 (74) 4 (67) 12 (100) 10 (83) 5 (71) 7 (39)
  2-vessels disease 13 (18) 4 (21) 2 (33) 0 2 (17) 1 (14) 1 (6)
  3-vessels disease 2 (3) 1 (5) 0 0 0 1 (14) 0
 Type of culprit lesion
  Thrombotic 34 (46) 19 (100) 5 (83) 8 (67) 2 (17) 0 0
  Complex 13 (18) 0 1 (17) 5 (42) 5 (42) 0 2 (11)
Revascularization 52 (70) 19 (100) 6 (100) 12 (100) 11 (92) 0 3 (17)
 Thrombus aspiration 29 (56) 19 (100) 5 (83) 5 (42) 0 1 (33)
 Stent 46 (88) 18 (95) 6 (100) 11 (92) 11 (92) 2 (67)
 Drug-eluting stent 8 (11) 1 (5) 1 (17) 2 (17) 3 (25) 1 (33)
 CABG 0 (0) 0 0 0 0
  Final TIMI flow grade 3 46 (88) 16 (84) 6 (100) 9 (75) 11 (100) 3 (100)
  Grade 2 6 (12) 3 (16) 0 3 (25) 0 0
  Grade 0–1 0 (0) 0 0 0 0 0
Max CPK in AMI patients n = 44 n = 19 n = 5 n = 9 n = 7 n = 2 n = 2
  Median 2010 2658† 2911 2133 195† 414 655
  IQR 676–2913 2010–2983 720–2917 962–2898 151–438 265–562 378–932
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characteristics (ROC) curve with the area under the curve, 
presented together with the 95 % confidential interval (95 % 
CI) or ±standard error. Comparisons between biomark-
ers were performed by an analysis of the differences of the 
diagnostic performances with McNemar’s test, Fisher’s exact 
test or Pearson’s Chi-square test, as appropriate. The statisti-
cal analysis of differences between the area under the ROC 
curve of each biomarker was performed using the method 
reported by Hanley et al. [10]. Kruskal–Wallis test was used 
for an overall analysis among more than 3 groups, then if sta-
tistically significant, Mann–Whitney U test was performed to 
compare each other. These analyses of differences between 
biomarkers were adjusted by Bonferroni correction within the 
multiple comparisons for the flow status of the culprit lesion, 
the culprit coronary artery group, and the number of diseased 
vessels. The statistical analyses were performed using the 
SPSS® software program version 20.0.0 (IBM® Corporation, 
New York, NY, USA). The values of the validated cardiac bio-
markers were described as box plot in figures to describe the 
differences of the various CAG findings. Values of p < 0.05 
were considered to indicate statistical significance.
Results
Angiographic finding and final diagnosis
Angiographic findings of the study population are shown 
in Table 2. The CAG study revealed that 25 patients (34 %) 
had total occlusion as the culprit lesions. Those with total 
occlusion and poor collateral (Rentrop’s collateral flow 
grade 0 or 1) were all diagnosed as STEMI (n = 19). In 
those with total occlusion and good collateral (grade 2 or 
3), there were 3 patients with STEMI, 2 with NSTEMI, 
and one with unstable AP. In the all patients with subtotal 
occlusion (n = 12), good collateral flow (grade 2 or 3) was 
not observed, and there were 9 patients with STEMI, and 
3 with unstable AP. In those with severe stenosis of %DS 
90–99 % but TIMI flow grade 3, there were 3 patients with 
STEMI, 4 with NSTEMI, and 5 with unstable AP. There 
were 2 patients with STEMI who showed CAG-proved 
spastic stenosis but no organic stenosis. In those with cul-
prit stenosis of %DS 0–75 %, there were one patient with 
STEMI, one with NSTEMI, 3 with unstable AP, 2 with 
stable AP, 5 with VSA, and 6 without CAD. With the more 
severe lesion in angiographic finding, the more frequently 
the patient was diagnosed as AMI (Table 2).
Cardiac biomarkers with stratification by angiographic 
findings
The concentrations of the cardiac biomarkers were strati-
fied by angiographic severity of the culprit lesion (Fig. 2). 
Those with the total occlusion and poor collateral showed 
significantly higher values of hs-TnT compared with those 
in other culprit lesions; however, c-TnT did not discrimi-
nate difference in the other angiographic findings. H-FABP 
discriminated those with total occlusion regardless of 
Fig. 2  Cardiac biomarkers with 
stratification by severity of the 
culprit lesion
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collateral grade, but did not discriminate those with signifi-
cant stenosis with subtotal occlusion or %DS 90–99 %. In 
those with spastic stenosis, only hs-TnT increased higher 
than the cut-off value (i.e., 14 ng/L).
In patients with severe obstructive lesions (total occlu-
sion, subtotal occlusion (TIMI 2), and %DS 90–99 % 
TIMI 3), hs-TnT presented positive in 35 of 49 patients 
(71 %), meanwhile H-FABP presented positive in 25 of 
49 patients (51 %) (p = 0.021). Moreover, in patients with 
%DS 90–99 % which were all diagnosed as AMI or UAP, 
hs-TnT presented positive in 11 of 12 patients (92 %); how-
ever, H-FABP presented positive in only 5 of 12 patients 
(42 %) (p = 0.063). Overall, hs-TnT could diagnose 
severe obstructive lesions with 72 % of accuracy with a 
tendency of higher values compared with H-FABP (59 %, 
p = 0.064).
The detail of angiographic findings and invasive 
treatment
Coronary vessels with significant stenosis (%DS > 75 %) 
were found at right coronary artery in 25 patients (34 %), 
left anterior descending artery in 29 (39 %), left circum-
flex artery in 8 (11 %), and lateral branch in 6 (8 %), and 
there was no patient with left main trunk disease. Number 
of the diseased vessels (%DS > 75 %) was one-vessel in 
50 (68 %), two-vessels in 13 (18 %), and triple-vessels in 
2 (3 %). The type of the culprit lesion for ACS was throm-
botic lesion in 34 (46 %). The methods of revasculariza-
tion were thrombus aspiration for 29, stent implantation for 
46, and drug-eluting stent for 8. Final TIMI flow grade was 
classified to grade 3 in 46 patients, grade 2 in 6, and grade 
0 or 1 in none of this study population.
Diagnostic performance to decide PCI for ACS
To predict angiographic ACS lesions for emergency PCI, 
the diagnostic performances of the cardiac biomarkers 
are shown in Table 3. The sensitivity and the NPV of hs-
TnT were the highest among the validated biomarkers. 
The areas under the ROC curves of hs-TnT and H-FABP 
presented the highest value (0.75); however, these did not 
reach to the statistical significance in comparison with the 
other 2 biomarkers. The ROC-optimized cut-off values of 
hs-TnT, c-TnT, CK-MB, and H-FABP were 18, 11, 3.0, and 
4.6 ng/mL, respectively. The rule-in cut-off values were 84, 
67, 15.1, and 68 ng/mL, respectively. Although H-FABP 
showed the highest sensitivity among the validated bio-
markers at ROC-optimized cut-off values, the cut-off value 
of H-FABP was less than the currently used cut-off (6.2 ng/
mL). The all rule-in cut-off values of the validated biomark-
ers showed very low sensitivity. At the ROC-optimized 
Table 3  Diagnostic performance to predict the angiographic ACS lesion underwent PCI with 95 % CI
ACS acute coronary syndrome, PCI percutaneous coronary intervention, CI confidential interval, PPV positive predictive value, NPV negative 
predictive value, ROC receiver-operator characteristics, AUC area under the curve
† p value <0.001 in comparison with hs-TnT
‡ p value <0.01
§ p value <0.05
% (95% CI) Cut-off Sensitivity Specificity PPV NPV ROC-AUC
hs-TnT
 Current cut-off 14 ng/L 69 % (54–81)† 60 % (37–87) 83 % (69–93) 50 % (32–68) 0.75 (0.62–0.88)
 ROC-optimized 18 ng/L 63 % (48–76) 74 % (52–90) 84 % (69–94) 47 % (30–65)
 Rule-in cut-off 84 ng/L 12 % (4–24) 100 % (93–100) 100 % (54–100) 53 % (43–63)
c-TnT
 Current cut-off 30 ng/L 24 % (12–37)†, ‡ 87 % (77–97) 80 % (52–96) 34 % (22–47) 0.67 (0.54–0.80)
 ROC-optimized 11 ng/L 49 % (35–63) 87 % (66–97) 89 % (72–98) 43 % (29–59)
 Rule-in cut-off 67 ng/L 8 % (2–19) 100 % (85–100) 100 % (40–100) 33 % (22–45)
CK-MB
 Current cut-off 5.0 ng/mL 29 % (17–44)†, § 87 % (68–97) 83 % (59–97) 36 % (23–50) 0.68 (0.55–0.81)
 ROC-optimized 3.0 ng/mL 63 % (48–76) 70 % (47–87) 82 % (66–92) 46 % (29–63)
 Rule-in cut-off 15.1 ng/mL 2 % (0–10) 100 % (85–100) 100 % (3–100) 32 % (21–43)
H-FABP
 Current cut-off 6.2 ng/mL 51 % (37–65)‡, § 78 % (56–93) 84 % (66–95) 42 % (27–58) 0.75 (0.63–0.88)
 ROC-optimized 4.6 ng/mL 71 % (56–83) 78 % (56–93) 88 % (74–96) 55 % (36–72)
 Rule-in cut-off 68 ng/mL 6 % (1–16) 100 % (85–100) 100 % (29–100) 32 % (22–45)
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cut-off values, only hs-TnT was appropriate to diagnose 
angiographic ACS lesions with enough analytical precision.
Cardiac markers and the angiographic characteristics
Location of the culprit vessel
The values of the cardiac biomarkers classified by location 
of the culprit vessel were presented as box plot (Fig. 3). In 
multiple comparisons for each cardiac biomarker group, 
there was statistical significance in the hs-TnT (p < 0.05). 
Patients with left circumflex artery (LCX) and those with 
right coronary artery (RCA) showed significantly higher 
value compared with patients without significant stenotic 
lesion. The patients with LCX admitted later than those 
with RCA lesion, and there were significant differences 
in time from the onset to presentation [median (IQR); 250 
(173–586) min in LCX vs 165 (100–300) min in RCA, 
p = 0.008].
With stratification of the number of the diseased ves-
sels, there was statistical significance only in H-FABP 
(p = 0.019) and a tendency in hs-TnT (p = 0.086) 
(Fig. 4). The values of the cardiac biomarkers were pre-
sented as box plot divided by having thrombotic lesion 
(Fig. 5). Interestingly, H-FABP showed near signifi-
cantly higher value (p = 0.05) in patients with throm-
botic lesion compared with those without thrombotic 
lesion.
Fig. 3  Cardiac biomarkers classified by the location of the culprit vessel
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Discussion
The diagnostic performances to predict angiographic 
ACS lesion
The present HsTnT-iNET subanalysis has first addressed 
the correlations between angiographic ACS lesions indi-
cated for emergency PCI and cardiac biomarkers, thereby 
to clarify the usefulness of the validated biomarkers for the 
decision making of emergency PCI. Importantly, this study 
reflected the contemporary clinical practice for ACS, which 
means that all patients admitted to tertiary cardiovascular 
center during early phase from onset of chest pain were 
prospectively enrolled in this study. In this subanalysis, we 
reviewed the detail of angiographic findings from the raw 
data of CAG, and investigated the association between the 
cardiac biomarkers and the characteristics of ACS lesions. 
Cut-off values of AMI definition had been revised, and 
recently the 99th percentile value of upper reference limit 
with coefficient of variance less than 10 % has been rec-
ommended in the current guidelines [11–13]. Although the 
degree of the increase reflected the degree of the risk in the 
ACS conditions, it seemed uninfluential for the decision of 
therapeutic strategy to discriminate AMI from the patients 
Fig. 4  Cardiac biomarkers with stratification by number of the diseased coronary arteries
Fig. 5  Cardiac biomarkers for the patients having thrombotic lesion
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with mild increase of cardiac troponin in non ST-segment 
elevation type ACS. The early invasive strategy has been 
recommended for the ACS patients with high-risk features 
such as persistent resting angina pain, TnT >100 ng/L, per-
sistent ST-T deviation, pulmonary edema, and refractory 
arrhythmia [13].
The present study has provided rational strategy using 
hs-TnT measurement in the ACS practice. Namely, the pre-
sent study has demonstrated the newly defined thresholds 
as the ROC-optimized cut-off value of hs-TnT (18 ng/mL) 
and the rule-in cut-off value (84 ng/mL). These cut-off val-
ues had been established by the most reliable method such 
as coronary angiography but not cardiac biomarker. Dif-
ference in the threshold from 14 to 18 ng/mL may reduce 
the case number of emergency angiography; meanwhile, 
the threshold of 84 ng/mL can be used as the absolute indi-
cation to achieve early revascularization. Although these 
thresholds of hs-TnT can be measured with 10 % CV 
(13.5 ng/mL), the ROC-optimized cut-off values except 
for hs-TnT were less than the confidential limits to apply. 
These results suggested that only hs-TnT could be used in 
such situations.
Collateral flow grade and hs‑TnT
In the literature, however, there were no reports addressing 
the relation between the status of collateral flow and the 
change of cardiac biomarkers. In this study, the values of 
the cardiac biomarkers were stratified by the collateral flow 
grades. Patients with total occlusion and poor collateral 
showed significantly higher values of hs-TnT compared 
with those in other culprit lesions, which suggested hs-TnT 
as the most sensitive marker for impending and critical 
myocardial injury.
Elevation of hs‑TnT and Myocardial infarction associated 
with Coronary Spasm
Myocardial infarction caused by coronary spasm has been 
well known [14–16]. In the investigations by spasm prov-
ocation tests for ACS patients [17, 18], more than half of 
AMI patients were provoked coronary spasm by acetyl-
choline test, and coronary artery spasm was negligible 
in the clinical practice of ACS. In the present study, 14 
patients were associated with coronary spasm after adju-
dicating the diagnosis, 4 of 7 patients (57 %) with CAG-
proved coronary spasm presented positive hs-TnT, and 2 
patients of those were diagnosed as MI. Meanwhile, 4 of 
25 patients without significant stenosis (%DS > 75), throm-
bosis, ulceration, and irregularity were diagnosed as AMI. 
These patients might be suffered from coronary spasm and 
should receive the benefits of coronary vasodilator to avoid 
recurrent ischemia or life-threatening event. The clinical 
implication of positive hs-TnT in the patients with coronary 
spasm remained to be established.
Differences between hs‑TnT and H‑FABP for PCI decision
In the present study, both hs-TnT and H-FABP demon-
strated powerful diagnostic performance to predict angio-
graphic ACS lesion indicated for emergency PCI. How-
ever, there were some differences between hs-TnT and 
H-FABP. Hs-TnT could detect the patients with severe 
obstructive stenoses likely to indicate emergency PCI with 
significantly more accuracy than H-FABP. Second, in ACS 
patients with  %DS 90–99 % TIMI 3, hs-TnT could diag-
nose in 91 % of those, with a tendency of higher compared 
with H-FABP (42 %).
Limitations
There are several limitations associated with this study. 
First, all participant institutions were tertiary centers 
equipped with coronary care units, therefore patients with 
more severe conditions were likely to be included in this 
study. In fact, the study cohort had a much higher preva-
lence of STEMI patients compared with previous reports. 
Second, the number of patients might be not enough to pur-
sue the significant differences in comparisons for the vari-
ous findings of CAG. Finally, indication of PCI for the sten-
otic lesion in the condition with ACS symptom has been 
largely charged by judgment of the operator, and impact of 
coronary spasm for ACS could not be determined by CAG. 
These might be the unavoidable limitation to investigate the 
correlation between CAG and the cardiac biomarker.
Conclusions
The present study first demonstrated the correlation 
between the angiographic culprit lesions for ACS and the 
cardiac biomarkers. For prediction of ACS lesions requir-
ing emergency PCI, hs-TnT had the highest sensitivity to 
predict ACS lesions and the newly defined thresholds can 
provide more strategic implications for angiographic find-
ings. Both hs-TnT and H-FABP discriminated different 
characteristics of ACS culprit lesions indicated for emer-
gency PCI.
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